[1]刘贤国,徐红玉,朱 江.原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展[J].陕西医学杂志,2023,52(10):1438-1441.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
　LIU Xianguo,XU Hongyu,ZHU Jiang.Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols[J].,2023,52(10):1438-1441.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
点击复制

原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年10期
页码:
1438-1441
栏目:
综 述
出版日期:
2023-10-05

文章信息/Info

Title:
Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols
作者:
刘贤国1; 2; 徐红玉2; 朱 江1
(1.四川大学华西医院肿瘤中心胸部肿瘤病房,四川 成都 610044; 2.三六三医院肿瘤科,四川 成都 610041)
Author(s):
LIU Xianguo; XU Hongyu; ZHU Jiang
(Thoracic Cancer Ward of Cancer Center,West China Hospital,Sichuan University,Chengdu 610044,China)
关键词:
原发性肝癌;  门静脉癌栓;  导管肝动脉化疗栓塞术;  介入治疗;  放疗
Keywords:
Primary liver cancer;  Portal vein cancer thrombus;  Transcatheter hepatic arterial chemoembolization;  Interventional therapy;  Radiotherapy
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2023.10.036
文献标志码:
A
摘要:
门静脉癌栓(PVTT)是原发性肝癌(HCC)常见并发症之一,严重影响患者生活质量和预后。PVTT 形成的原因复杂,机制尚不完全清楚。目前,除传统手术治疗外,以经导管肝动脉化疗栓塞术(TACE)为主联合其他介入治疗手段如:射频消融、放射治疗、靶向药物、免疫治疗等联合应用可取得良好效果。现对原发性肝癌伴门静脉癌栓产生机制及TACE联合其他介入治疗方案的应用进展做一综述,以期对肝癌的临床诊疗工作提供帮助。
Abstract:
Portal vein cancer thrombus(PVTT)is one of the common complications of primary liver cancer(HCC),which seriously affects the quality of life and prognosis of patients.The causes of PVTT formation are complex and the mechanism is not fully understood.At present,in addition to traditional surgical treatment,transcatheter hepatic arterial chemoembolization(TACE)combined with other interventional treatment methods such as radiofrequency ablation,radiotherapy,targeted drugs,immunotherapy and other combined applications can achieve good results.This article reviews the mediator of primary liver cancer with portal vein cancer and the application progress of TACE combined with other interventional programs,in order to provide help for the clinical diagnosis and treatment of liver cancer.

参考文献/References:

[1] 许晓宇,陆 意,钱夏婧,等.原发性肝癌合并门静脉癌栓的治疗进展与挑战[J].浙江医学,2022,44(3):314-319.
[2] 张凤博,张春娇,姜洪池.肝细胞癌合并门静脉癌栓的治疗现状及进展[J].中华消化外科杂志,2021,20(5):568-573.
[3] Matsushita N,Douhara A,Ueno H,et al.Intraductal papillarymucinous carcinoma with portal vein tumor thrombus and multifocal liver metastasis:An autopsy case[J].Mol Clin Oncol,2021,14(5):101.
[4] Mehta N,Yao F.Liver Transplantation After downstaging of hepatocellular carcinoma with portal vein tumor thrombus using yttrium-90 radioembolization:Pipe dream or reality?[J].Liver Transpl,2021,27(12):1706-1708.
[5] Ohkoshi-Yamada M,Kamimura K,Shibata O,et al.Efficacy and safety of the radiotherapy for liver cancer:Assessment of local controllability and its role in multidisciplinary therapy[J].Cancers,2020,12(10):2955.
[6] 曹洪祥,黄 平.肝细胞癌合并门静脉癌栓的治疗现状[J].肝胆胰外科杂志,2023,35(4):252-256.
[7] 李 玮,王 雯,齐梦剑,等.肝癌合并门静脉癌栓局部治疗进展[J].中国实用外科杂志,2023,43(5):591-596.
[8] 闫慧文,王欣慧,江宇泳,等.肝癌合并门静脉癌栓的微创治疗研究进展[J].医学综述,2019,25(15):2918-2922.
[9] 单人锋.Aurora-B基因促肝癌转移及其机制的实验研究[D].南昌:南昌大学,2019.
[10] 张修平.PRMT1在肝癌中的功能和机制研究及肝癌伴门静脉癌栓手术决策的临床研究[D].上海:中国人民解放军海军军医大学,2019.
[11] 张 宁,李 楠,袁东晨,等.汤仁仙.HBC通过NEU1调控肝癌细胞中基因表达的初步研究[J].中国病原生物学杂志,2021,16(1):2622-2631.
[12] Dhanasekaran R,Nault JC,Roberts LR,et al.Genomic medicine and implications for hepatocellular carcinoma prevention and therapy[J].Gastroenterology,2019,156(2):492-509.
[13] 樊潇霄.肝癌和癌栓的全基因组甲基化分析及差异基因的相关临床特征研究[D].杭州:浙江大学,2020.
[14] 伍柳玉,胡艳玲,刘顺秦,等.ACACB基因DNA甲基化/过表达的肝癌细胞株MHCC97H增殖侵袭迁移能力变化观察[J].山东医药,2021,61(33):1-5.
[15] 包海林,谢 群.MIF、sICAM-1、visfatin及AFP在PHC患者血清中的表达及与患者病情判断及肝纤维化的关系研究[J].中国中西医结合消化杂志,2020,28(2):104-107.
[16] Bort A,Sánchez BG,De-Miguel I,et al.Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells[J].Mol Biol Rep,2020,47(4):2635-2647.
[17] 朱霞霞,王 琦,李 帅,等.RPB5介导蛋白与HBx蛋白共表达对肝癌HepG2细胞凋亡的影响[J].临床检验杂志,2015,33(3):219-222.
[18] 伊陈禾.肝细胞癌(HCC)门静脉癌栓(PVTT)形成的分子机制研究进展[J].复旦学报,2019,46(2):261-266.
[19] Hernndez-Aquino E,Muriel P.Beneficial effects of naringenin in liver diseases:Molecular mechanisms[J].World J Gastroenterol,2018,24(16):1679-1707.
[20] 郭 萍,袁志平.三维适形放疗联合TACE治疗中晚期肝癌患者的早期疗效[J].肝脏,2020,25(12):1269-1271,1285.
[21] 王亚运,胡 欢,王世垚,等.三维适形放疗联合TACE治疗肝癌伴门静脉癌栓的有效性与安全性的Meta分析[J].西北国防医学杂志,2018,39(11):704-710.
[22] 姚红军,胡 静,袁灿亮.经导管动脉栓塞化疗联合调强放疗治疗中晚期肝癌的疗效及预后观察[J].癌症进展,2022,20(19):1996-1998.
[23] 田永巍,蒋 强,李 宁,等.125I粒子植入联合TACE治疗原发性肝癌的效果及对患者IL-8和IFN-γ水平的影响[J].实用癌症杂志,2022,37(3):451-454.
[24] 陈 健,王艳梅,王 修,等.CT引导下125I放射性粒子植入治疗肝癌门静脉癌栓的临床效果[J].中国保健营养,2019,29(21):372.
[25] 欧盛秋,韦长元,马亦龙,等.125I放射性粒子联合TACE治疗原发性肝癌的临床观察[J].中华肿瘤防治杂志,2014,21(17):1373-1375.
[26] 伍 路,沈 锋.微波消融联合化疗栓塞治疗肝细胞肝癌伴门脉癌栓的临床疗效[J].中国临床医学,2017,24(2):272-276.
[27] 蒋雪超,崔洪霞,张 娟,等.TACE联合RFA治疗无法手术的肝细胞癌疗效及预后分析[J].肿瘤药学,2015(5):379-383.
[28] 曹绍华,王庆庆,张金冉.索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响[J].陕西医学杂志,2020,49(5):615-618.
[29] 刘昊元,刘凯元.TACE联合索拉非尼治疗老年肝癌合并肝静脉癌栓的疗效及生存情况[J].中国老年学杂志,2021,41(16):3420-3423.
[30] 尹 灿.TACE联合PD-1抑制剂治疗中晚期肝细胞癌疗效的回顾性研究[D].重庆:重庆医科大学,2021.

相似文献/References:

[1]郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析*[J].陕西医学杂志,2019,(7):850.
[2]李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,(7):873.
　LI Xun,ZHANG Xianglin..Efficacy observation and TSGF change in primary hepatocellular carcinoma by TACE and entecavir[J].,2019,(10):873.
[3]陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
　TAO Lin.Application of antibiotics and risk factors of secondary infection in patients with primary liver cancer after chemotherapy[J].,2023,52(10):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
[4]刘立友,吴东洋,蔡青山,等.原发性肝癌组织中层粘连蛋白3、黏着斑激酶蛋白表达及其与患者临床病理特征和预后关系研究[J].陕西医学杂志,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
　LIU Liyou,WU Dongyang,CAI Qingshan,et al.Expression of LAMA3 and FAK proteins in primary liver cancer and their relationship with clinicopathological features and prognosis of patients[J].,2023,52(10):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
[5]李晓勤,王 群,何晓兰,等.多模式镇痛对原发性肝癌患者休斯顿疼痛情况调查表评分及血清结合珠蛋白水平的影响[J].陕西医学杂志,2024,(4):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
　LI Xiaoqin,WANG Qun,HE Xiaolan,et al.InfLuences of multimodal analgesia on HPOI score and serum haptoglobin level in patients with hepatocellular carcinoma[J].,2024,(10):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
[6]孟凡岗,刘文宇,甄立军,等.原发性肝癌组织长链非编码RNA JPX、微小RNA-371a-5p表达水平及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,(8):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
　MENG Fangang,LIU Wenyu,ZHEN Lijun,et al.Expression levels of long non-coding RNA JPX and microRNA-371a-5p in primary liver cancer tissues and their relationship with 5-year prognosis of patients after surgery[J].,2024,(10):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]

备注/Memo

备注/Memo:
基金项目:四川省医学青年创新科研计划课题(Q20074)
更新日期/Last Update: 2023-10-07